Risk factors for cognitive decline in non-demented elders with amyloid-beta positivity
Our study may facilitate the understanding of the potential pathological processes in AD and provide novel targets for the prevention of cognitive decline among participants with Aβ positivity.
Authors
- Qiong‐Yao Li (ORCID: https://orcid.org/0000-0003-4202-3270)
- He‐Ying Hu
- Liangyu Huang (ORCID: https://orcid.org/0000-0003-4701-6221)
- Anyi Wang (ORCID: https://orcid.org/0000-0002-5211-8938)
- Lan Tan (ORCID: https://orcid.org/0000-0002-8759-7588)
- Hao Hu (ORCID: https://orcid.org/0000-0002-4604-6333)
- Chu-Yun Xiao
Institutions
- Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1186/s13195-024-01554-0
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Brigham and Women's Hospital
- Biogen
- University of Southern California
- Ohio State University
- Meso Scale Diagnostics
- Northwestern University
- Wake Forest University
- Cleveland Clinic
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Georgetown University
- Case Western Reserve University
- Novartis Pharmaceuticals Corporation
- Dartmouth College
- McGill University
- University of South Florida
- Northern California Institute for Research and Education
- USF Health Byrd Alzheimer's Institute
- National Natural Science Foundation of China
- Eisai
- Jewish General Hospital
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- University of California, Davis
- University of California, San Francisco
- University of California, Irvine
- Canadian Institutes of Health Research